March 3, 2026Open Access

Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry

Key Points

High renal response rates were observed with belimumab-based triple therapy, indicating its effectiveness.
Extrarenal response rates also showed substantial improvement, emphasizing comprehensive treatment benefits.
Data analysis from the BEL-SPAIN Registry highlights real-world efficacy and safety in clinical practice.
Effects demonstrate potential for increased GC-sparing outcomes and treat-to-target strategies in therapy.

Abstract

BEL-based triple therapy is effective and safe in proliferative LN, achieving high renal and extrarenal response rates, substantial GC-sparing and treat-to-target outcomes in real-world practice.

Bookmark

View Full Paper

Cite This Study

Vidal-Montal et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75b7fc6e9836116a22ed1 https://doi.org/https://doi.org/10.1136/lupus-2025-001825

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper